FBT – First Trust NYSE Arca Biotechnology Index Fund
First Trust NYSE Arca Biotechnology Index Fund (FBT) is a Health ETF, issued by First Trust, $3B in assets, 0.54% expense ratio.
Returns as of Oct 23, 2026: 1 week +2.1%, 1 year +44.9%.
Equal-dollar weighted index of 30 leading biotechnology companies. Invests 90% in index-component securities.
Top holdings
- HALO – Halozyme Therapeutics Inc, 3.8%
- ALKS – Alkermes Plc, 3.7%
- BGNE – BeiGene Ltd, 3.6%
- EXEL – Exelixis Inc, 3.6%
- REGN – Regeneron Pharmaceuticals Inc, 3.5%
- BIIB – Biogen Inc, 3.4%
- RGEN – Repligen Corporation, 3.4%
- INCY – Incyte Corporation, 3.4%
- ADMA – ADMA Biologics Inc, 3.4%
- VRTX – Vertex Pharmaceuticals Inc, 3.4%
- VCYT – Veracyte Inc, 3.4%
- NTRA – Natera Inc, 3.3%
- TGTX – TG Therapeutics Inc, 3.3%
- BMRN – Biomarin Pharmaceutical Inc, 3.3%
- AMGN – Amgen Inc, 3.3%
- TARS – Tarsus Pharmaceuticals Inc, 3.3%
- ARGX – argenx NV ADR, 3.3%
- GMAB – Genmab AS, 3.3%
- NBIX – Neurocrine Biosciences Inc, 3.3%
- TECH – Bio-Techne Corp, 3.2%
- NEO – NeoGenomics Inc, 3.2%
- GILD – Gilead Sciences Inc, 3.2%
- BNTX – BioNTech SE, 3.2%
- BRKR – Bruker Corporation, 3.2%
- UTHR – United Therapeutics Corporation, 3.2%